Share on Pinterest New research suggests that HIV drugs may have a protective effect against Alzheimer’s. Willie B. Thomas/Getty Images Researchers at UVA Health have found that a class of HIV ...

The drugs, called NRTIs, have the potential to prevent a million cases of Alzheimer's every year, the researchers believe. UVA Health scientists are calling for clinical trials testing the ...

As researchers make progress in understanding how Alzheimer's disease develops, there are growing opportunities for healthy research participants to learn their risk of developing Alzheimer's ...

FIRST DEGREE MURDER. MORE AMERICANS THAN EVER HAVE ALZHEIMER’S. AROUND 7.2 MILLION PEOPLE 65 AND OLDER DO. THAT’S ACCORDING TO THE LATEST ESTIMATE. BUT MORE ARE TRYING A MEDICATION ...

Alzheimer's-type biomarker profiles were most frequently observed in early-onset Alzheimer's disease, late-onset Alzheimer's disease, and mixed Alzheimer's and vascular dementia.Other diagnostic ...

For the first time, the number of Americans living with Alzheimer’s disease (AD) has surpassed 7 million, according to the Alzheimer’s Disease Facts and Figures report released this week.

Alzheimer’s disease now affects more than seven million people in the U.S., and nearly four in five Americans say they would want to know if they have it before symptoms emerge. This data comes ...

New treatments and blood tests could change detection and treatments. New treatments and simple blood tests could change how doctors detect and treat Alzheimer's disease, according to a new report ...

The number of people with Alzheimer's dementia in the U.S. exceeded 7 million for the first time, new data from the Alzheimer's Association showed. An estimated 7.2 million Americans ages 65 and ...

Alzheimer’s disease is commonly thought of as an older person’s illness. But new research from Columbia University and the University of North Carolina reveals early signs of Alzheimer’s ...

Recent Alzheimer's research has led to FDA-approved treatments that slow cognitive decline, such as Lecanemab and Donanemab. New diagnostic tools like PET scans and blood biomarker tests allow for ...

A long-term human trial has found that a discontinued drug halved the presentation of early-onset Alzheimer's disease in people with a genetic predisposition to the devastating condition.